BioAscent is pleased to share the recent publication of its successful collaboration with researchers at the University of Glasgow in the Journal of Medicinal Chemistry. Led by Professors Andrew Jamieson and Graeme Milligan, together with PhD student Michael Malone, this study reports the discovery of a new class of orthosteric GPR84 antagonists with significant therapeutic potential.

GPR84 is an orphan G protein‑coupled receptor (GPCR) strongly implicated in inflammatory and fibrotic conditions. Antagonists of this receptor have attracted interest due to their promising therapeutic potential in the treatment of a range of inflammatory disorders. This newly published work describes the discovery, optimisation and validation of a novel chromenopyrrole GPR84 antagonist series encompassing medicinal chemistry, molecular modelling, and detailed pharmacology. The combined effort delivered a potent, selective lead compound, providing a strong foundation for future therapeutic development.

Professor Andrew Jamieson, University of Glasgow, commented:

“Our collaboration with BioAscent was instrumental in advancing this programme. Their expertise in synthetic and medicinal chemistry enabled us to rapidly explore the chemical space and optimise promising compounds, ultimately allowing the team to identify a high‑quality lead. The seamless integration of BioAscent’s industry experience with our academic research significantly strengthened the project and helped drive it towards a successful outcome.”

Dr Angus Morrison, Director of Chemistry at BioAscent, said:

"It was a real pleasure working with Andrew and Michael on this. The mix of academic and industry perspectives, combined with Michael's persistence, was key to moving the science forward. Taking the chromenopyrrole series to a validated lead was a significant milestone for the team and provides further valuable insights into the structural requirements for high-affinity orthosteric inhibition of GPR84."

With a strong and varied track record in GPCR drug discovery, BioAscent is proud to have contributed to this important research, and we look forward to following the programme as it progresses further. Learn more about our expertise here.